221 related articles for article (PubMed ID: 22745051)
1. Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs.
Taroumian S; Knowles SL; Lisse JR; Yanes J; Ampel NM; Vaz A; Galgiani JN; Hoover SE
Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1903-9. PubMed ID: 22745051
[TBL] [Abstract][Full Text] [Related]
2. Management of asymptomatic coccidioidomycosis in patients with rheumatic diseases.
Bilal J; Kollampare S; Bode B; Lisse JR; Hoover SE; Sudano D; Ampel NM
Rheumatol Int; 2019 Jul; 39(7):1257-1262. PubMed ID: 31065743
[TBL] [Abstract][Full Text] [Related]
3. Coccidioidomycosis in rheumatology patients: incidence and potential risk factors.
Mertz LE; Blair JE
Ann N Y Acad Sci; 2007 Sep; 1111():343-57. PubMed ID: 17363440
[TBL] [Abstract][Full Text] [Related]
4. Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis.
Ampel NM; Giblin A; Mourani JP; Galgiani JN
Clin Infect Dis; 2009 Jan; 48(2):172-8. PubMed ID: 19072555
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
6. What matters to patients and physicians when considering biologic therapy for rheumatoid arthritis.
Lisicki R; Chu L
Postgrad Med; 2008 Sep; 120(3):154-60. PubMed ID: 18824833
[TBL] [Abstract][Full Text] [Related]
7. Bronchiectasis in rheumatoid arthritis: report of four cases and a review of the literature--implications for management with biologic response modifiers.
Lieberman-Maran L; Orzano IM; Passero MA; Lally EV
Semin Arthritis Rheum; 2006 Jun; 35(6):379-87. PubMed ID: 16765715
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
9. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
[TBL] [Abstract][Full Text] [Related]
10. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
11. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.
Stine JG; Khokhar OS; Charalambopoulos J; Shanmugam VK; Lewis JH
Arthritis Care Res (Hoboken); 2010 May; 62(5):704-11. PubMed ID: 20461789
[TBL] [Abstract][Full Text] [Related]
12. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
14. Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction.
Homer D; Nightingale P; Jobanputra P
Musculoskeletal Care; 2009 Jun; 7(2):78-92. PubMed ID: 18792423
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice.
Montag K; Gingold M; Boers A; Littlejohn G
Intern Med J; 2011 Jun; 41(6):450-5. PubMed ID: 20403067
[TBL] [Abstract][Full Text] [Related]
16. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
[TBL] [Abstract][Full Text] [Related]
17. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
18. Coccidioidomycosis in elderly persons.
Blair JE; Mayer AP; Currier J; Files JA; Wu Q
Clin Infect Dis; 2008 Dec; 47(12):1513-8. PubMed ID: 18990061
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary coccidioidomycosis.
Thompson GR
Semin Respir Crit Care Med; 2011 Dec; 32(6):754-63. PubMed ID: 22167403
[TBL] [Abstract][Full Text] [Related]
20. Universal fungal prophylaxis and risk of coccidioidomycosis in liver transplant recipients living in an endemic area.
Kahn A; Carey EJ; Blair JE
Liver Transpl; 2015 Mar; 21(3):353-61. PubMed ID: 25482428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
